Search Results - "Giza, Adam"

The Factorial Survey: The Impact of the Presentation Format of Vignettes on Answer Behavior and Processing Time

Authors: Shamon, Hawal Dülmer, Hermann Giza, Adam

Source: Sociological Methods & Research. Feb 2022 51(1):396-438.

Peer Reviewed: Y

Page Count: 43

Descriptors: Vignettes, Surveys, Response Style (Tests), Reaction Time, Foreign Countries, Adults, Age Differences, Educational Attainment

Geographic Terms: Germany

Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.

Authors: Kutsch, Nadine Giza, Adam Robrecht, Sandra et al.

Source: European Journal of Haematology. Aug2024, Vol. 113 Issue 2, p235-241. 7p.

Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.

Authors: Simon, Florian Giza, Adam Robrecht, Sandra et al.

Source: Leukemia & Lymphoma. Dec2022, Vol. 63 Issue 14, p3299-3306. 8p.

Are Female Offenders Underreported Compared to Male Offenders? A German-Greek Comparison of Crime Reporting, Rating of Offence Seriousness and Personal Experiences of Victimisation.

Authors: Stroh, Michael Eichinger, Matthias Giza, Adam et al.

Source: European Journal on Criminal Policy & Research. Dec2016, Vol. 22 Issue 4, p635-653. 19p. 6 Charts.

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group.

Authors: von Tresckow, Julia Heyl, Nikola Robrecht, Sandra et al.

Source: Annals of Hematology. Nov2023, Vol. 102 Issue 11, p3083-3090. 8p.

IGLV3-21^R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Authors: Yosifov DY Robrecht S Giza A et al.

Source: HemaSphere [Hemasphere] 2026 Jun 15; Vol. 10 (6), pp. e70385. Date of Electronic Publication: 2026 Jun 15 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Authors: Riecke A Robrecht S Yosifov DY et al.

Source: Blood [Blood] 2026 Jun 18. Date of Electronic Publication: 2026 Jun 18.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Authors: Fürstenau M Niemann CU Robrecht S et al.

Source: Blood [Blood] 2026 Jun 18; Vol. 147 (25), pp. 3025-3038.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Authors: Langerbeins P Giza A Robrecht S et al.

Source: American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1620-1623. Date of Electronic Publication: 2024 May 17.

Publication Type: Letter

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Authors: Cramer P von Tresckow J Fink AM et al.

Source: American journal of hematology [Am J Hematol] 2024 Jun; Vol. 99 (6), pp. 1192-1195. Date of Electronic Publication: 2024 Apr 05.

Publication Type: Letter; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Authors: Al-Sawaf O Fürstenau M Giza A et al.

Source: Blood [Blood] 2025 Nov 13; Vol. 146 (20), pp. 2406-2416.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.

Authors: Goede V Fischer K Robrecht S et al.

Source: Blood advances [Blood Adv] 2025 May 27; Vol. 9 (10), pp. 2431-2435.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Authors: Fürstenau M Robrecht S Schneider C et al.

Source: Blood [Blood] 2025 Mar 20; Vol. 145 (12), pp. 1282-1292.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.

Authors: Fürstenau M Giza A Stumpf T et al.

Source: American journal of hematology [Am J Hematol] 2021 Dec 01; Vol. 96 (12), pp. E457-E460. Date of Electronic Publication: 2021 Oct 08.

Publication Type: Letter

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.

Authors: Bloehdorn J Braun A Taylor-Weiner A et al.

Source: Nature communications [Nat Commun] 2021 Sep 13; Vol. 12 (1), pp. 5395. Date of Electronic Publication: 2021 Sep 13.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Authors: Fürstenau M Giza A Weiss J et al.

Source: Blood [Blood] 2024 Jul 18; Vol. 144 (3), pp. 272-282.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.

Authors: Langerbeins P Giza A Robrecht S et al.

Source: Blood [Blood] 2024 Jun 20; Vol. 143 (25), pp. 2588-2598.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Authors: Huber H Tausch E Schneider C et al.

Source: Blood [Blood] 2023 Sep 14; Vol. 142 (11), pp. 961-972.

Publication Type: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

Authors: Fürstenau M Weiss J Giza A et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Oct 03; Vol. 28 (19), pp. 4203-4211.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.

Authors: Cramer P Fürstenau M Robrecht S et al.

Source: The Lancet. Haematology [Lancet Haematol] 2022 Oct; Vol. 9 (10), pp. e745-e755. Date of Electronic Publication: 2022 Aug 18.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE